Skip to content

Comparing the Effect of LTS and Air-Q sp3G LMA Use on Gastric Insufflation Using Ultrasound

Comparing the Effect of Laryngeal Tube Suction (LTS) and Air-Q sp3G Laryngeal Mask Airway (LMA) Use on Gastric Insufflation and Volume Using Ultrasound

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07196137
Enrollment
101
Registered
2025-09-29
Start date
2025-09-29
Completion date
2026-01-29
Last updated
2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elective Surgeries, Gastric Insufflation, Gastric Ultrasonography, Laryngeal Masks Comparison

Keywords

Laryngeal Mask, Airway Management, Ultrasonography, Child

Brief summary

The primary objective of the study is to evaluate gastric insufflation during the use of two different airway devices (Laringeal Tube Suction and Air Q sp3G Laryngeal Mask. The secondary objectives of the study are to assess these two airway devices in terms of perioperative complications.

Detailed description

During general anesthesia, various devices are used to secure the airway. Supraglottic airway devices (SGAs) are among these and are used safely for short surgical procedures. Although SGAs are used to provide an easy and safe airway, none of them seal the trachea and ventilate only the lungs in the way that endotracheal intubation (ETT) does. Positive pressure ventilation provided at the supraglottic level cannot prevent air from escaping into the esophagus and, consequently, the stomach. Gastric distension is associated with perioperative complications such as nausea, vomiting, and aspiration, and is considered an undesirable condition by anesthesiologists. The study aims to compare the Laryngeal Tube Suction and the Air Q sp3G Laryngeal Mask in terms of gastric insufflation. By measuring the diameters of the gastric antrum and recording their changes throughout the case, this study intend to evaluate the effectiveness and reliability of the two airway devices. ASA (American Society of Anesthesiologist) I-III class pediatric patients between the ages of 1-12 who will undergo elective surgery under general anesthesia will be included in the study. Randomisation will be done with a sealed envelope. The blinded researcher will collect and record data without knowing which airway device was chosen. Blind researcher will do gastric ultrasound measurements with Butterfly IQ+ ultrasound. Another researcher will insert the airway device and after insertion patients head will be covered, this researcher will not involve during data collection. After the data is collected, the airway device releated data will be recorded by non-blind researcher seperately.

Interventions

None listed

Sponsors

Ankara City Hospital Bilkent
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

Patients with an ASA score of I-III for whom a supraglottic airway (SGA) is planned. Operation time less than 2 hours. Patients who have read and accepted the informed consent form. Patients between the ages of 1 and 12, or their guardians, will be included in the study.

Exclusion criteria

Patients who do not meet perioperative fasting criteria. Patients whose stomachs are not considered empty during the initial gastric ultrasound. Patients with a known difficult airway. Patients with oropharyngeal or laryngeal anomalies. Patients who require the use of neuromuscular blockers. Patients with a history of a previously failed SGA placement. Patients with known reflux. Patients who do not give consent will not be included in the study.

Design outcomes

Primary

MeasureTime frameDescription
Gastric Antral Cross Sectional Area (T0)Just before anesthesia inductionFirst gastric measurement: Before anesthesia induction gastric ultrasound will be done and gastric antrum cross sectional area will be recorded by blinded researcher
Gastric Antral Cross Sectional Area (T1)Right after the SGA is placed following anesthesia induction.Second gastric measurement: after anesthesia induction and before the start of surgery gastric ultrasound will be done and gastric antrum cross sectional area will be recorded by blinded researcher
Gastric Antral Cross Sectional Area (T2)Just before the end of anesthesia, after the surgery is completedThird measurement: Just before the end of anesthesia, after the surgery is completed gastric ultrasound will be done and gastric antrum cross sectional area will be recorded by blinded researcher.

Secondary

MeasureTime frameDescription
LTS Cuff Pressure MeasurementJust after inserting a Laryngeal Tube SuctionIf the choosen airway device is an LTS, after inserting LTS a cuff pressure measurement will be done by nonblind researcher. For masking the device that used even if a measurement is not taken, it will be treated as if it were.
Maximum Airway Pressure (PPeak)IntraoperativeThe highest pressure measured by the mechanical ventilator will be recorded.
Minimum SaturationIntraoperativeThe lowest measured saturation value.
SpasmIntraoperative and/or postoperative 2 hoursIncidence of spasm
The time taken for airway device placement and failed placementIntraoperativeThe time from the moment the airway device is touched until end-tidal CO2 is detected (Second)
Postoperative Sore ThroatPostoperative 2 hoursIncidence of sore throat assessed by direct questioning
Postoperative Nausea and VomittingPostoperative 2 hoursIncidence of post operative nausea and vomitting assessed by direct questioning
Presence of blood on the supraglottic airwayJust after removing the SGANonblinded researcher will check if there is blood contamination on the SGA after removing it.
Postoperative CoughPostoperative 2 hoursIncidence of Cough assessed by direct questioning or physical examination
Need for nebulized medications or cool mist.Postoperative 2 hoursNeed for nebulized medications or cool mist for spasm or cough

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 8, 2026